IceCure Reports Financial & Operational Results for the First Half of 2025
Provided By PR Newswire
Last update: Aug 13, 2025
$10 million two-times over-subscribed rights offering creates cash runway to anticipated FDA marketing authorization decision for ProSense® in women aged 70+ with early-stage low risk breast cancer
Read more at prnewswire.com
